Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients
about
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantationEffects of Adoptive Transfer of Tolerogenic Dendritic Cells on Allograft Survival in Organ Transplantation Models: An Overview of Systematic ReviewsHigh-risk corneal allografts: A therapeutic challengeSensitivity of Dendritic Cells to Microenvironment SignalsProspective Clinical Testing of Regulatory Dendritic Cells in Organ TransplantationTolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal BlockageTissue engineering tools for modulation of the immune responseImmunotherapy with myeloid cells for tolerance inductionDendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivoImmature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro.iPSC-Derived Regulatory Dendritic Cells Inhibit Allograft Rejection by Generating Alloantigen-Specific Regulatory T Cells.The innate immune system in allograft rejection and tolerance.Berberine induces dendritic cell apoptosis and has therapeutic potential for rheumatoid arthritis.Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates.Proteomic analysis reveals innate immune activity in intestinal transplant dysfunction.Immune tolerance induction by integrating innate and adaptive immune regulators.CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease.Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.Chimerism after organ transplantationBlocking of the B7-CD28 pathway increases apoptosis induced in activated T cells by in vitro-generated CD95L (FasL) positive dendritic cells.Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation.Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritiThe lost chord: microchimerism and allograft survival.Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells.Flt3L combined with rapamycin promotes cardiac allograft tolerance by inducing regulatory dendritic cells and allograft autophagy in mice.Molecular pathways: myeloid complicity in cancer.Dendritic cells, tolerance induction and transplant outcome.Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimusEx vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantationFunctional modulation of dendritic cells to suppress adaptive immune responses.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Apoptosis and transplantation tolerance.Dendritic cells, T cell tolerance and therapy of adverse immune reactions.Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cellsTolerogenic dendritic cells and their role in transplantation.IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival.Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction.Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation.Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCsDendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.
P2860
Q21284774-D41981B9-46E7-4786-B567-9752700FEC16Q26739998-15F83702-7756-4579-8515-05F75B5BA0F5Q26751483-CBB05F45-5B44-4953-BC36-1706766A98E6Q26752817-21C9161C-8F2C-4089-8F8C-979721A2E2B3Q26767458-7FD86C49-6107-4C68-8D0C-B213E5005B8BQ26778646-D0FFA0A9-0729-4194-96EF-D2971EA68DA5Q27023419-412C9027-2BD7-4E51-AA6C-007161369716Q27687406-4EDE1549-8EA2-4C9E-91D9-846BF9DE598FQ30080006-559D8CEE-41C8-4326-A2BC-24D1E4F7E7C9Q33493421-BEC4C4D6-0F04-4747-8077-70212042449EQ33659263-7C9B6351-C39D-40D2-AFA6-08113B563E0AQ33732470-8CD834B7-2ED6-4A3F-A8EB-4AB09AE3A15FQ33772722-7907D70A-3D70-4565-B0F2-CA405930E2C4Q33804736-EC4ACBDB-959D-4B12-9FE9-3BBA4D387258Q33884369-0F6AF63D-4F6D-4D4D-AC7A-604C1CEB8BB3Q33907609-8D110476-1CFA-4DBF-8DA7-9DA41DCFC35EQ33980867-353AB46E-3D55-4E3C-8CE1-761E3158F9B5Q33986118-17CA7192-88CE-45FB-B4FD-4C1F35F9C16AQ34201706-F154E5A8-1C2E-4C34-9A31-5F00FDD8A17DQ34245691-8BF698E1-9F83-4B5B-91D9-9E6EE4FD6185Q34282217-D9C113BF-2DE5-4CD5-B4E4-D674950D58E2Q34300891-17788021-FEFB-47ED-9D23-D0F9CE92F205Q34359678-382AB432-4396-4EE3-B225-C692FA8E62B4Q34379951-2222464A-1D3F-4E82-8664-7AA0950A080DQ34441235-89B56FA3-A080-4127-AED2-70411C0912C5Q34725969-247D1D8D-EFE4-4B93-B8F3-61377FC80389Q34740521-B0A9A211-A7F1-4F2F-9870-240D2F617B54Q34910186-DFA674D9-912D-47DF-B473-160EB0DDB191Q35085385-0EE26985-3F29-43C7-B40C-49630B6E69F5Q35093120-8ED84B7A-E6E0-48A9-A4DB-6E09B8B947D1Q35116303-22AD60AF-A83B-4CC2-9504-401E346612ACQ35129735-45B352FD-6CA2-448F-A96D-75B4836BC8FCQ35161161-4F4CA459-AD17-4D35-BBF2-B5D29148C21BQ35285735-1A8944EA-415A-4655-BE36-9B9A01BF86F3Q35341379-0396B4F2-ECF2-44EA-87BE-0C3C09F4BFDCQ35402371-A6026D5F-4E4A-439B-862F-08CD6B719EB5Q35583516-852D735B-459B-41D0-8F63-DD50F76B578EQ35865098-B4FC8878-4A38-4F2A-AB27-70F9DD643867Q36002657-0C85F80F-384A-45F1-95E5-8AD10A131078Q36014986-918C658C-6775-4E99-A6ED-FE9AACD32664
P2860
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@ast
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@en
type
label
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@ast
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@en
prefLabel
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@ast
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@en
P2093
P2860
P1433
P1476
Costimulatory molecule-deficie ...... nonimmunosuppressed recipients
@en
P2093
P2860
P304
P356
10.1097/00007890-199609150-00021
P577
1996-09-01T00:00:00Z